Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trialClinical Trial Published on 2022-06-072022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 임상, 진단, 치료법, 치료제, [키워드] 1:1 95% CI administration Adverse age Antigen assigned AstraZeneca block sizes blocked clinical clinical evaluation clinically collected conducted Course COVID-19 COVID-19 vaccination death dose double-blind Efficacy enrolled enrolment Europe evaluate event Fever finding for inclusion funding individual intramuscular intramuscular injections investigators involved Japan laboratory-confirmed SARS-CoV-2 infection Latin America less Mild moderate Moderate COVID-19 monoclonal antibody combination non-hospitalised occurred Older outcomes participant Phase 3 Placebo placebo-controlled study placebo-controlled trial prevent disease progression primary endpoint progression provided randomisation randomised Randomly receive Registered required respiratory tract risk reduction RT-PCR scale severe COVID-19 severity specimen Sponsor statistically stratified study drug Symptom symptom onset the disease the placebo group treating Treatment treatment group USA WHO [DOI] 10.1016/S2213-2600(22)00180-1 [Article Type] Clinical Trial
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine재조합 식물 기반 면역증강제 코로나19 백신의 효능 및 안전성Clinical Trial Published on 2022-06-022022-09-11 Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, 치료제, [키워드] 1:1 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant adverse event age Analysis AS03 assigned baseline candidate vaccine caused conducted coronavirus coronavirus disease Coronavirus disease 2019 CoVLP CoVLP+AS03 determine disease dose effective Efficacy Factor FIVE incidence injection intention-to-treat intention-to-treat population Intramuscular injection Local median age Median viral load Medicago Mild moderate occurred participant Participants participated Particle performed Phase 3 Placebo placebo group placebo-controlled trial plant plants polymerase post-hoc analysis prefusion produced Randomized receive recombinant respiratory Safety SARS-CoV-2 sequenced Sequencing seronegative severe acute respiratory syndrome Coronavirus Severe case Spectrum spike glycoprotein symptomatic symptomatic COVID-19 symptomatic infection System systemic adverse event systemic adverse events the median the placebo group the vaccine Trial two group two groups Vaccine vaccine efficacy vaccine group variant variants Viral Viral load viral sample Volunteer [DOI] 10.1056/NEJMoa2201300 PMC 바로가기 [Article Type] Clinical Trial
Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults성인에서 RBD-이량체 기반 코비드-19 백신 ZF2001의 효능 및 안전성Clinical Trial Published on 2022-06-022022-09-25 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, [키워드] 1:1 95% CI 95% confidence interval acute respiratory syndrome Adults adverse event Adverse reaction age aluminum Analysis assigned China Clinical Center clinical trials conducted coronavirus coronavirus disease Cutoff death deaths dimeric dose double-blind effective Efficacy efficacy analysis efficacy end point Follow-up hydroxide immunogenic incidence Indonesia large cohort Major MOST occurred Occurrence participant Participants phase 3 trial Placebo placebo-controlled primary end point primary end-point Randomized Randomly receive regimen reported Safe Safety safety analysis Science Serious Adverse Event shown Side-effect symptomatic technology the placebo group the receptor-binding domain Trial two groups vaccination Vaccine was performed ZF2001 [DOI] 10.1056/NEJMoa2202261 PMC 바로가기 [Article Type] Clinical Trial
Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19SARS-CoV-2에 대한 아프로티닌 치료: 중등도 COVID-19에 대한 범프로테아제 억제제의 안전성과 효능을 평가하기 위한 무작위 3상 연구Clinical Trial Published on 2022-06-012022-09-11 Journal: European Journal of Clinical Investigation [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] ACE2 addition administration Adverse reaction Adverse reactions anti-inflammatory properties anti-inflammatory property antiviral drug antivirus Aprotinin cleave Clinical outcome clinical trial Composite Contact COVID-19 death discharge double-blind Efficacy evaluate follow-up period furin had no hospital Hospital admission Hospital stay Hospitalization hospitalized patient hospitalized patients host protease host proteases human respiratory viruses ICU admission IMPROVE incidence inhalation therapy inhibiting inhibitor Innate immunity less mechanism Moderate COVID-19 multicentre outcome oxygen Oxygen therapy parameter patients with COVID-19 performed placebo group Pneumonia profiles Protease inhibitor Randomized randomized trial required respiratory viruses resulting Safe Safety SARS-CoV-2 SARS-CoV-2 virus secondary endpoint Secondary endpoints Side effects significant difference significant differences Spanish Spike protein standard treatment the placebo group Treatment with COVID-19 [DOI] 10.1111/eci.13776 PMC 바로가기 [Article Type] Clinical Trial
Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI TrialRandomized Controlled Trial Published on 2022-06-012022-10-05 Journal: Advances in therapy [Category] COVID19(2023년), SARS, 임상, [키워드] breath clearance clinical status COVID-19 double-blind Dyspnoea ELOM-080 enhancement enhancer enrolment EudraCT evaluated exploratory exploratory study had no hospitalisation hospitalised IMPROVE Inflammatory less MCC MCC enhancement Mucociliary clearance Patient patients treated patients with COVID-19 per-protocol Placebo PPS Prospective randomised recruitment required respiratory respiratory diseases Safety Shortness of breath. significant effect supplemental oxygen the placebo group therapy treat treating COVID-19 Trial [DOI] 10.1007/s12325-022-02135-z PMC 바로가기 [Article Type] Randomized Controlled Trial
The effect of prostacyclin infusion on markers of endothelial activation and damage in mechanically ventilated patients with SARS-CoV-2 infectionSARS-CoV-2 감염이 있는 기계 환기 환자의 내피 활성화 및 손상 마커에 대한 프로스타사이클린 주입의 효과Randomized Controlled Trial Published on 2022-06-012022-09-11 Journal: Journal of critical care [Category] COVID19(2023년), SARS, 바이오마커, 임상, [키워드] Activation Adult patients baseline Biomarker Biomarkers blood sample Blood samples CD40L change changes in collected COVID-19 damage decrease endothelial Endothelium glycocalyx groups marker mechanically ventilated mechanically ventilated patient mechanically ventilated patients median medians not differ Organ failure P-selectin Patient pilot study Placebo placebo group plasma Plasma levels prostacyclin protective effect Randomized Randomized controlled trial reduction in SARS-CoV-2 SARS-COV-2 infection selectin significantly syndecan Syndecan-1 the placebo group thrombomodulin with COVID-19 [DOI] 10.1016/j.jcrc.2022.154010 PMC 바로가기 [Article Type] Randomized Controlled Trial
Fermented Carica papaya and Morinda citrifolia as Perspective Food Supplements for the Treatment of Post-COVID Symptoms: Randomized Placebo-Controlled Clinical Laboratory Study코로나 이후 증상 치료를 위한 관점 식품 보충제로서의 발효 카리카 파파야 및 모린다 시트리폴리아: 무작위 위약 대조 임상 실험실 연구Randomized Controlled Trial Published on 2022-05-252022-09-11 Journal: Nutrients [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] added addition alleviate Anti-inflammatory effects antioxidant antioxidant activity ATP Carica papaya clinical clinical laboratory clinical symptom Clinical symptoms computer tomography COVID-19 disease cytokine Cytokines delta variant disease Electrocardiography expression fermented food supplements food IL-17A IL-6 IL-8 immune Laboratory leukocyte long-lasting mechanisms metabolite microbiota Moderate COVID-19 modulating Morinda citrifolia Nitrate nitrates nitrates/nitrites nitric oxide nitrite nitrites omicron oral-nasal-pharyngeal microbiota participant Patient per day performed phagocyte phagocytosis physical physical endurance placebo group placebo-controlled polymorphonuclear leukocyte post-COVID symptoms pro-inflammatory cytokines questionnaire Randomized significantly single-center Symptoms the placebo group Treatment protocol tropical variant virus were assessed [DOI] 10.3390/nu14112203 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 VaccineBNT162b2 코비드-19 백신 3차 접종의 안전성 및 효능Clinical Trial Published on 2022-05-192022-09-25 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 임상, 진단, 치료법, [키워드] 95% confidence interval active immunization acute respiratory syndrome Administered age assigned BNT162b2 BNT162b2 vaccine booster coronavirus coronavirus disease Critical dose Efficacy evaluated event Evidence Follow-up Infection injected median median interval myocarditis of BNT162b2 Older pandemic participant Pfizer-BioNTech phase 3 trial Placebo placebo-controlled provided Randomized reported Safety SARS-CoV-2 SARS-COV-2 infection second dose systemic reactogenicity the median the placebo group the vaccine Vaccine [DOI] 10.1056/NEJMoa2200674 PMC 바로가기 [Article Type] Clinical Trial
Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trialResearch article Published on 2022-05-122022-10-05 Journal: EClinicalMedicine [Category] 유전자 메커니즘, 임상, [키워드] 1:1 95% CI analyses Analysis BCG BCG vaccination Breastfeeding Cape Capital childhood computation computing Council COVID-19 COVID-19 testing died Donor double-blind Dream Efficacy enrolled Epigenetic evaluated Evidence female finding FIVE foundation functional funding had no hazard ratio healthcare healthcare worker hospitalisation hypersensitivity hypothesised Immunocompromised Infrastructure innate immune system introduced Investment IQR median age medical doctors morbidity morbidity and mortality non-specific Nurses occurred pandemic participant phase 3 trial placebo-controlled trial pregnant Prevent PROTECT provided randomised recruited reduction Registered resource respiratory tract infection Respiratory tract infections Safety SARS-CoV-2 SARS-COV-2 infection severe COVID-19 disease severity South Africa statistically significant Swedish Symptoms the placebo group trained immunity Treatment Tuberculosis Vaccine were assessed [DOI] 10.1016/j.eclinm.2022.101414 [Article Type] Research article
Effect of Early Treatment with Ivermectin among Patients with Covid-19Covid-19 환자에서 Ivermectin의 조기 치료 효과Randomized Controlled Trial Published on 2022-05-052022-09-25 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, [키워드] acute respiratory syndrome Adaptive platform trial Admission adverse events Analysis assigned Bayesian credible interval Brazil caused clinics conducted coronavirus coronavirus disease defined Disease progression dose double-blind early diagnosis Effect Efficacy events finding hospital Hospital admissions Hospitalization incidence Intervention involved Ivermectin ivermectin group modified intention-to-treat no significant effect observation outcome Outpatient Patient patients per-protocol analysis Placebo placebo-controlled primary analysis progression public health randomization Randomized Randomly receive recruited regimen reported risk risk factor SARS-CoV-2 secondary outcome Symptom symptomatic the disease the placebo group Trial worsening [DOI] 10.1056/NEJMoa2115869 PMC 바로가기 [Article Type] Randomized Controlled Trial